Examination of lipid nanoparticle loaded hydrogels for localized silencing of spermidine/spermine acetyl transferase-1 (SATl) expression in tumor and enhanced radiation response

Radiation therapy is an important part of cancer treatment. However, many tumor cells have the ability to survive radiation exposure resulting in a reduced overall effectiveness and increased risk of treatment failure. Spermidine/spermine acetyl transferase-1 (SATl) is a cellular enzyme over-expressed in many cancers including brain, lung and breast . We have identified a way to knock-down levels of SATl in cells using small nano-sized particles carrying an RNA-based compound that interferes with the production of SATl. Treatment of glioblastoma tumor cells with these nanoparticles enhanced the killing action of radiation. As the sensitizing effects of the nanoparticles were not observed in normal cells, we belief this approach can be developed into safe and effective method for sensitizing tumor to radiation exposure. The proposed proof-of-concept studies involve the development and testing of an injectable drug delivery platform (which we are calling RestorTM) for localized and sustained delivery of SATl targeted nanoparticles to improve and restore radiation responses in a variety of cancers including brain, lung, and breast. Completion of studies will provide necessary proof-of-concept for the effectiveness of RestorTM as a localized radiation sensitizing agent for improved treatment of cancers

Faculty Supervisor:

Donald Miller

Student:

Partner:

Biomark Diagnostics Inc.

Discipline:

Life Sciences

Sector:

Professional, scientific and technical services

University:

University of Manitoba

Program: